Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial
Journal of Cachexia, Sarcopenia and Muscle · 2024
DOI: 10.1002/jcsm.13445 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Ambarish Pandey und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Liraglutide, Obesity, Overweight. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Background
Excess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat and adverse muscle composition is unknown.
Methods
This is a pre‐specified secondary analysis of a randomized, double‐blind, placebo‐controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue and ectopic fat among adults without diabetes with body mass index ≥30 kg/m 2 or ≥27 kg/m 2 and metabolic syndrome. Participants were randomly assigned to a once‐daily subcutaneous injection of liraglutide (target dose 3.0 mg) or matching placebo for 40 weeks. Body fat distribution and muscle composition was assessed by magnetic resonance imaging at baseline and 40‐week follow‐up. Muscle composition was described by the combination of thigh muscle fat and muscle volume. Treatment difference (95% confidence intervals [CI]) was calculated by least‐square means adjusted for baseline thigh muscle fat. The association between changes in thigh muscle fat and changes in body weight were assessed using Spearman correlation coefficients. The effect of liraglutide versus placebo on adverse muscle composition, denoted by high thigh muscle fat and low thigh muscle volume, was explored.
Results
Among the 128 participants with follow‐up imaging (92.2% women, 36.7% Black), median muscle fat at baseline was 7.8%. The mean percent change in thigh muscle fat over median follow‐up of 36 weeks was −2.87% among participants randomized to liraglutide ( n = 73) and 0.05% in the placebo group (absolute change: −0.23% vs. 0.01%). The estimated treatment difference adjusted for baseline thigh muscle fat was −0.24% (95% CI, −0.41 to −0.06, P ‐value 0.009). Longitudinal change in thigh muscle fat was significantly associated with change in body weight in the placebo group but not the liraglutide group. The proportion of participants with adverse muscle composition decreased from 11.0% to 8.2% over follow‐up with liraglutide, but there was no change with placebo.
Conclusions
In a cohort of predominantly women with overweight or obesity in the absence of diabetes, once‐daily subcutaneous liraglutide was associated with a reduction in thigh muscle fat and adverse muscle composition compared with placebo. The contribution of muscle fat improvement to the cardiometabolic benefits of liraglutide requires further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
- Department of Cardiology, Texas Heart Institute, Houston, TX, USA.
- AMRA Medical and Linköping University, Linköping, Sweden.
- Department of Health, Medicine and Caring Sciences, Division of Diagnostics and Specialist Medicine, Linköping University, Linköping, Sweden.
- Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), and German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Förderung
- Novo Nordisk
Zitieren
APA
Pandey, A., Patel, K. V., Segar, M. W., Ayers, C., Linge, J., Leinhard, O. D., Anker, S. D., Butler, J., Verma, S., Joshi, P. H., & Neeland, I. J. (2024). Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13445
Vancouver
Pandey A, Patel KV, Segar MW, Ayers C, Linge J, Leinhard OD, et al. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13445
BibTeX
@article{Pandey2024,
author = {Pandey, Ambarish and Patel, Kershaw V and Segar, Matthew W and Ayers, Colby and Linge, Jennifer and Leinhard, Olof D and Anker, Stefan D and Butler, Javed and Verma, Subodh and Joshi, Parag H and Neeland, Ian J},
title = {Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
doi = {10.1002/jcsm.13445}
}
EUVIMED